Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity

Jamila Laoukili, Alexander Constantinides, Emma C E Wassenaar, Sjoerd G Elias, Danielle A E Raats, Susanne J van Schelven, Jonathan van Wettum, Richard Volckmann, Jan Koster, Alwin D R Huitema, Simon W Nienhuijs, Ignace H J T de Hingh, René J Wiezer, Helma M U van Grevenstein, Inne H M Borel Rinkes, Djamila Boerma, Onno Kranenburg

Research output: Contribution to journalArticleAcademicpeer-review

21 Downloads (Pure)

Abstract

BACKGROUND: Peritoneal metastases (PM) in colorectal cancer (CRC) are associated with therapy resistance and poor survival. Oxaliplatin monotherapy is widely applied in the intraperitoneal treatment of PM, but fails to yield clinical benefit. We aimed to identify the mechanism(s) underlying PM resistance to oxaliplatin and to develop strategies overcoming such resistance.

EXPERIMENTAL DESIGN: We generated a biobank consisting of 35 primary tumour regions and 59 paired PM from 12 patients. All samples were analysed by RNA sequencing. We also generated a series of PM-derived organoid (PMDO) cultures and used these to design and test strategies to overcome resistance to oxaliplatin.

RESULTS: PM displayed various hallmarks of aggressive CRC biology. The vast majority of PM and paired primary tumours belonged to the Consensus Molecular Subtype 4 (CMS4). PMDO cultures were resistant to oxaliplatin and expressed high levels of glutamate-cysteine ligase (GCLC) causing detoxification of oxaliplatin through glutathione synthesis. Genetic or pharmacological targeting of GCLC sensitised PMDOs to a 1-h exposure to oxaliplatin, through increased platinum-DNA adduct formation.

CONCLUSIONS: These results link oxaliplatin resistance of colorectal PM to their CMS4 status and high reducing capacity. Inhibiting the reducing capacity of PM may be an effective strategy to overcome PM resistance to oxaliplatin.

Original languageEnglish
Pages (from-to)1824-1833
Number of pages10
JournalBritish Journal of Cancer
Volume126
Issue number12
Early online date22 Feb 2022
DOIs
Publication statusPublished - 1 Jun 2022

Fingerprint

Dive into the research topics of 'Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity'. Together they form a unique fingerprint.

Cite this